Stepping into that territory, even with good intentions, puts your client at real risk and puts your business at real liability
In 2023 ADA guidelines said that, alongside lower hypoglycemia and obesity, GLP-1 agonists are highly recommended drugs among patients with clinical ASCVD risks (eg, prior myocardial infarction, stroke), as they lower cardiovascular risk
The higher end of this range is better for anyone doing resistance training, anyone over 50, or anyone who has already lost significant weight
In vivo longitudinal proton magnetic resonance spectroscopy on neonatal hypoxic-ischemic rat brain injury: neuroprotective effects of acetyl-L-carnitine
Does compounded tirzepatide from PlexusDx cause different side effects than brand-name Mounjaro
Both are involved in regulating blood sugar levels [1]